Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

Status Withdrawn

Clinical Trial Summary

This study evaluates the addition of docosahexaenoic acid (DHA) to eye patching in the treatment of residual amblyopia in children ages 3 to 18 years old. Two thirds of participants will receive DHA along with eye patching, while one third of participants will receive a placebo along with eye patching.

Clinical Trial Description

Amblyopia is the most common cause of monocular visual impairment in children and adults. There are well established therapies for this condition, which typically involve eye patching or atropine eye drops. Despite these therapies, a substantial proportion of treated patients have some degree of residual amblyopia, even when treatment takes place early during the critical period visual development. Investigators have tried to augment standard amblyopia treatment with medications that appear to promote visual cortex plasticity, thus addressing the neuronal pathogenesis of amblyopia. For example, levodopa, was described as a possible drug to treat amblyopia due to its ability to enhance cortical plasticity. While the rationale behind such treatments is promising, results from well-powered clinical trials have not shown a statistically significant effect of these treatments. Docosahexaenoic acid (DHA) is a long chain polyunsaturated fatty acid (LCPUFA) that is considered essential for the maturation of the developing brain and retina. DHA, which is commercially available a nutritional supplement, has been added to infant formula, with studies showing that it improves visual development in premature infants. Randomized studies have shown that DHA supplementation of infant formula results in higher visual acuity in infants. Our proposal is aimed at conducting a prospective randomized pilot study to provide a preliminary assessment of the efficacy and safety of DHA combined with daily ocular occlusion therapy in children and teenagers with residual amblyopia. To our knowledge, this would be the first study aiming to treat amblyopia with DHA. If found to be effective, DHA may be considered a safe and inexpensive adjunct to our conventional means of treating amblyopia. ;

Study Design

Related Conditions & MeSH terms

Amblyopia

Clinical Trial Details

NCT number	NCT03402789
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	January 1, 2024
Completion date	December 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04238065` - A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia	N/A
Completed	`NCT04432181` - Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
Terminated	`NCT02767856` - Regimens of Intermittent Occlusion Therapy for Amblyopia in Children	N/A
Completed	`NCT02458846` - Efficacy of Visual Screening in Ontario	N/A
Completed	`NCT01190813` - Levodopa for the Treatment of Residual Amblyopia	Phase 3
Completed	`NCT01109459` - Multimodal Physician Intervention to Detect Amblyopia	N/A
Completed	`NCT04313257` - Monocular Action Video Game Treatment of Amblyopia	N/A
Completed	`NCT04315649` - Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops	N/A
Completed	`NCT05223153` - OCT-A and Amblyopia
Recruiting	`NCT05522972` - Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games	N/A
Completed	`NCT01430247` - Vision Screening for the Detection of Amblyopia	N/A
Completed	`NCT02200211` - Study of Binocular Computer Activities for Treatment of Amblyopia	N/A
Withdrawn	`NCT04959422` - Assuring Ophthalmologic Follow up	N/A
Active, not recruiting	`NCT05612568` - 5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
Recruiting	`NCT03655912` - Binocular Visual Therapy and Video Games for Amblyopia Treatment.	N/A
Recruiting	`NCT06150391` - Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program	N/A
Completed	`NCT03754153` - Binocularly Balanced Viewing Study	N/A
Terminated	`NCT02246556` - Dichoptic Virtual Reality Therapy for Amblyopia in Adults	Phase 1
Withdrawn	`NCT02594358` - Caffeine in Amblyopia Study	Phase 1/Phase 2
Completed	`NCT02003235` - Assessment of Device for Treatment of Amblyopia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.